Improvement of Monoclonal Antibody Production in Hybridoma Cells by Dimethyl Sulfoxide

Hybridoma cultures are routinely used as a source for monoclonal antibody (mAb) production necessary for preclinical evaluation. However, these cultures typically have low volumetric and specific productivities. In this article, we examined the use and the timing of addition of dimethyl sulfoxide (D...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biotechnology progress 2003, Vol.19 (1), p.158-162
Hauptverfasser: Ling, Wai Lam W., Deng, Liang, Lepore, Joseph, Cutler, Collette, Cannon-Carlson, Susan, Wang, Yan, Voloch, Marcio
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 162
container_issue 1
container_start_page 158
container_title Biotechnology progress
container_volume 19
creator Ling, Wai Lam W.
Deng, Liang
Lepore, Joseph
Cutler, Collette
Cannon-Carlson, Susan
Wang, Yan
Voloch, Marcio
description Hybridoma cultures are routinely used as a source for monoclonal antibody (mAb) production necessary for preclinical evaluation. However, these cultures typically have low volumetric and specific productivities. In this article, we examined the use and the timing of addition of dimethyl sulfoxide (DMSO) as a medium additive to improve mAb production in our hybridoma clone 19 (c19) cultures. From shake flask studies, we defined the optimal DMSO concentration and time of addition for improved productivity. This timing coordinated with high cell viability and density. Hybridoma cultures treated with DMSO up to 0.3% (v/v) possessed cell densities and viabilities comparable to untreated control. We demonstrated that 0.2% (v/v) DMSO added to shake flask cultures at their maximal viable cell densities resulted in a 2‐fold increase in specific mAb production. This procedure was scaleable up to 20 L Cellbags (Wave Bioreactors) with similar titer improvement. Moreover, DMSO treatment did not affect the bioactivity or glycosylation profiles of the mAb.
doi_str_mv 10.1021/bp020068d
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73009970</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>18697371</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4588-a0e8bb542456f79d65ad8db5313f873eaf640dd0110ea234df2d548232c8f5ed3</originalsourceid><addsrcrecordid>eNqF0EFvFCEYBmBibOzaevAPGC6a9DD1AwaGOda13TapbaOrNV4IM0BEmWEdZrTz70V3056MJzg87wfvh9BzAscEKHndbIACCGkeoQXhFAoBjD1GC1lxUVQ1k_voaUrfAECCoE_QPqG8YkDqBfp00W2G-NN2th9xdPhd7GMbYq8DPulH30Qz45shmqkdfeyx7_H53AzexE7jpQ0h4WbGb31nx69zwB-m4OKdN_YQ7Tkdkn22Ow_Qx7PT9fK8uLxeXSxPLou25FIWGqxsGl7SkgtX1UZwbaRpOCPMyYpZ7UQJxgAhYDVlpXHU8FJSRlvpuDXsAL3azs0lfkw2jarzqc3_0r2NU1K5JdR1Bf-FRIq6YhXJ8GgL2yGmNFinNoPv9DArAurPttX9trN9sRs6NZ01D3K33gxe7oBOrQ5u0H3r04MreU0EE9nB1v3ywc7_flG9Wd-8_3vNkWIb8Wm0d_cRPXxXIhfh6vZqpeSqPrv98nmtrthvVI6lOQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>18697371</pqid></control><display><type>article</type><title>Improvement of Monoclonal Antibody Production in Hybridoma Cells by Dimethyl Sulfoxide</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Ling, Wai Lam W. ; Deng, Liang ; Lepore, Joseph ; Cutler, Collette ; Cannon-Carlson, Susan ; Wang, Yan ; Voloch, Marcio</creator><creatorcontrib>Ling, Wai Lam W. ; Deng, Liang ; Lepore, Joseph ; Cutler, Collette ; Cannon-Carlson, Susan ; Wang, Yan ; Voloch, Marcio</creatorcontrib><description>Hybridoma cultures are routinely used as a source for monoclonal antibody (mAb) production necessary for preclinical evaluation. However, these cultures typically have low volumetric and specific productivities. In this article, we examined the use and the timing of addition of dimethyl sulfoxide (DMSO) as a medium additive to improve mAb production in our hybridoma clone 19 (c19) cultures. From shake flask studies, we defined the optimal DMSO concentration and time of addition for improved productivity. This timing coordinated with high cell viability and density. Hybridoma cultures treated with DMSO up to 0.3% (v/v) possessed cell densities and viabilities comparable to untreated control. We demonstrated that 0.2% (v/v) DMSO added to shake flask cultures at their maximal viable cell densities resulted in a 2‐fold increase in specific mAb production. This procedure was scaleable up to 20 L Cellbags (Wave Bioreactors) with similar titer improvement. Moreover, DMSO treatment did not affect the bioactivity or glycosylation profiles of the mAb.</description><identifier>ISSN: 8756-7938</identifier><identifier>EISSN: 1520-6033</identifier><identifier>DOI: 10.1021/bp020068d</identifier><identifier>PMID: 12573019</identifier><identifier>CODEN: BIPRET</identifier><language>eng</language><publisher>USA: American Chemical Society</publisher><subject>Antibodies, Monoclonal - biosynthesis ; Biological and medical sciences ; Cell Count ; Cell Survival - drug effects ; Culture Media - pharmacology ; Dimethyl Sulfoxide - pharmacology ; Dose-Response Relationship, Drug ; Fundamental and applied biological sciences. Psychology ; Hybridomas - drug effects ; Hybridomas - metabolism ; Quality Control</subject><ispartof>Biotechnology progress, 2003, Vol.19 (1), p.158-162</ispartof><rights>Copyright © 2003 American Institute of Chemical Engineers (AIChE)</rights><rights>2003 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4588-a0e8bb542456f79d65ad8db5313f873eaf640dd0110ea234df2d548232c8f5ed3</citedby><cites>FETCH-LOGICAL-c4588-a0e8bb542456f79d65ad8db5313f873eaf640dd0110ea234df2d548232c8f5ed3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1021%2Fbp020068d$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1021%2Fbp020068d$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,777,781,1412,4010,27904,27905,27906,45555,45556</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=14591636$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12573019$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ling, Wai Lam W.</creatorcontrib><creatorcontrib>Deng, Liang</creatorcontrib><creatorcontrib>Lepore, Joseph</creatorcontrib><creatorcontrib>Cutler, Collette</creatorcontrib><creatorcontrib>Cannon-Carlson, Susan</creatorcontrib><creatorcontrib>Wang, Yan</creatorcontrib><creatorcontrib>Voloch, Marcio</creatorcontrib><title>Improvement of Monoclonal Antibody Production in Hybridoma Cells by Dimethyl Sulfoxide</title><title>Biotechnology progress</title><addtitle>Biotechnol Progress</addtitle><description>Hybridoma cultures are routinely used as a source for monoclonal antibody (mAb) production necessary for preclinical evaluation. However, these cultures typically have low volumetric and specific productivities. In this article, we examined the use and the timing of addition of dimethyl sulfoxide (DMSO) as a medium additive to improve mAb production in our hybridoma clone 19 (c19) cultures. From shake flask studies, we defined the optimal DMSO concentration and time of addition for improved productivity. This timing coordinated with high cell viability and density. Hybridoma cultures treated with DMSO up to 0.3% (v/v) possessed cell densities and viabilities comparable to untreated control. We demonstrated that 0.2% (v/v) DMSO added to shake flask cultures at their maximal viable cell densities resulted in a 2‐fold increase in specific mAb production. This procedure was scaleable up to 20 L Cellbags (Wave Bioreactors) with similar titer improvement. Moreover, DMSO treatment did not affect the bioactivity or glycosylation profiles of the mAb.</description><subject>Antibodies, Monoclonal - biosynthesis</subject><subject>Biological and medical sciences</subject><subject>Cell Count</subject><subject>Cell Survival - drug effects</subject><subject>Culture Media - pharmacology</subject><subject>Dimethyl Sulfoxide - pharmacology</subject><subject>Dose-Response Relationship, Drug</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Hybridomas - drug effects</subject><subject>Hybridomas - metabolism</subject><subject>Quality Control</subject><issn>8756-7938</issn><issn>1520-6033</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0EFvFCEYBmBibOzaevAPGC6a9DD1AwaGOda13TapbaOrNV4IM0BEmWEdZrTz70V3056MJzg87wfvh9BzAscEKHndbIACCGkeoQXhFAoBjD1GC1lxUVQ1k_voaUrfAECCoE_QPqG8YkDqBfp00W2G-NN2th9xdPhd7GMbYq8DPulH30Qz45shmqkdfeyx7_H53AzexE7jpQ0h4WbGb31nx69zwB-m4OKdN_YQ7Tkdkn22Ow_Qx7PT9fK8uLxeXSxPLou25FIWGqxsGl7SkgtX1UZwbaRpOCPMyYpZ7UQJxgAhYDVlpXHU8FJSRlvpuDXsAL3azs0lfkw2jarzqc3_0r2NU1K5JdR1Bf-FRIq6YhXJ8GgL2yGmNFinNoPv9DArAurPttX9trN9sRs6NZ01D3K33gxe7oBOrQ5u0H3r04MreU0EE9nB1v3ywc7_flG9Wd-8_3vNkWIb8Wm0d_cRPXxXIhfh6vZqpeSqPrv98nmtrthvVI6lOQ</recordid><startdate>2003</startdate><enddate>2003</enddate><creator>Ling, Wai Lam W.</creator><creator>Deng, Liang</creator><creator>Lepore, Joseph</creator><creator>Cutler, Collette</creator><creator>Cannon-Carlson, Susan</creator><creator>Wang, Yan</creator><creator>Voloch, Marcio</creator><general>American Chemical Society</general><general>American Institute of Chemical Engineers</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>2003</creationdate><title>Improvement of Monoclonal Antibody Production in Hybridoma Cells by Dimethyl Sulfoxide</title><author>Ling, Wai Lam W. ; Deng, Liang ; Lepore, Joseph ; Cutler, Collette ; Cannon-Carlson, Susan ; Wang, Yan ; Voloch, Marcio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4588-a0e8bb542456f79d65ad8db5313f873eaf640dd0110ea234df2d548232c8f5ed3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Antibodies, Monoclonal - biosynthesis</topic><topic>Biological and medical sciences</topic><topic>Cell Count</topic><topic>Cell Survival - drug effects</topic><topic>Culture Media - pharmacology</topic><topic>Dimethyl Sulfoxide - pharmacology</topic><topic>Dose-Response Relationship, Drug</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Hybridomas - drug effects</topic><topic>Hybridomas - metabolism</topic><topic>Quality Control</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ling, Wai Lam W.</creatorcontrib><creatorcontrib>Deng, Liang</creatorcontrib><creatorcontrib>Lepore, Joseph</creatorcontrib><creatorcontrib>Cutler, Collette</creatorcontrib><creatorcontrib>Cannon-Carlson, Susan</creatorcontrib><creatorcontrib>Wang, Yan</creatorcontrib><creatorcontrib>Voloch, Marcio</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Biotechnology progress</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ling, Wai Lam W.</au><au>Deng, Liang</au><au>Lepore, Joseph</au><au>Cutler, Collette</au><au>Cannon-Carlson, Susan</au><au>Wang, Yan</au><au>Voloch, Marcio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Improvement of Monoclonal Antibody Production in Hybridoma Cells by Dimethyl Sulfoxide</atitle><jtitle>Biotechnology progress</jtitle><addtitle>Biotechnol Progress</addtitle><date>2003</date><risdate>2003</risdate><volume>19</volume><issue>1</issue><spage>158</spage><epage>162</epage><pages>158-162</pages><issn>8756-7938</issn><eissn>1520-6033</eissn><coden>BIPRET</coden><abstract>Hybridoma cultures are routinely used as a source for monoclonal antibody (mAb) production necessary for preclinical evaluation. However, these cultures typically have low volumetric and specific productivities. In this article, we examined the use and the timing of addition of dimethyl sulfoxide (DMSO) as a medium additive to improve mAb production in our hybridoma clone 19 (c19) cultures. From shake flask studies, we defined the optimal DMSO concentration and time of addition for improved productivity. This timing coordinated with high cell viability and density. Hybridoma cultures treated with DMSO up to 0.3% (v/v) possessed cell densities and viabilities comparable to untreated control. We demonstrated that 0.2% (v/v) DMSO added to shake flask cultures at their maximal viable cell densities resulted in a 2‐fold increase in specific mAb production. This procedure was scaleable up to 20 L Cellbags (Wave Bioreactors) with similar titer improvement. Moreover, DMSO treatment did not affect the bioactivity or glycosylation profiles of the mAb.</abstract><cop>USA</cop><pub>American Chemical Society</pub><pmid>12573019</pmid><doi>10.1021/bp020068d</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 8756-7938
ispartof Biotechnology progress, 2003, Vol.19 (1), p.158-162
issn 8756-7938
1520-6033
language eng
recordid cdi_proquest_miscellaneous_73009970
source MEDLINE; Wiley Online Library Journals Frontfile Complete
subjects Antibodies, Monoclonal - biosynthesis
Biological and medical sciences
Cell Count
Cell Survival - drug effects
Culture Media - pharmacology
Dimethyl Sulfoxide - pharmacology
Dose-Response Relationship, Drug
Fundamental and applied biological sciences. Psychology
Hybridomas - drug effects
Hybridomas - metabolism
Quality Control
title Improvement of Monoclonal Antibody Production in Hybridoma Cells by Dimethyl Sulfoxide
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T17%3A28%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Improvement%20of%20Monoclonal%20Antibody%20Production%20in%20Hybridoma%20Cells%20by%20Dimethyl%20Sulfoxide&rft.jtitle=Biotechnology%20progress&rft.au=Ling,%20Wai%20Lam%20W.&rft.date=2003&rft.volume=19&rft.issue=1&rft.spage=158&rft.epage=162&rft.pages=158-162&rft.issn=8756-7938&rft.eissn=1520-6033&rft.coden=BIPRET&rft_id=info:doi/10.1021/bp020068d&rft_dat=%3Cproquest_cross%3E18697371%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=18697371&rft_id=info:pmid/12573019&rfr_iscdi=true